Removal of autologous activated CD4-positive T lymphocytes also results in increased colony-forming units in patients with low and intermediate-1 risk myelodysplastic syndromes

European Journal of Haematology

Volumn 86, Issue 1, 2011, Pages 47-56

  Zheng, Zhang ^a   Feng, Xu ^a   Xiao, Li ^a   Qianqiao, Zhang ^a   Qi, He ^a   Lingyun, Wu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cell culture; Immunosuppression; Myelodysplastic syndrome; T lymphocyte

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; HLA DR15 ANTIGEN;

ADULT; AGED; ARTICLE; BONE MARROW; CD4+ T LYMPHOCYTE; CELL COUNT; CLONOGENESIS; COLONY FORMING UNIT; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TH1 CELL;

AUTOIMMUNITY; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELL COUNT; CELLS, CULTURED; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MYELODYSPLASTIC SYNDROMES; RECEPTORS, CCR5; RISK ASSESSMENT; STEM CELLS; TH1 CELLS;

EID: 78650105625     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01535.x     Document Type: Article

References (28)

1. Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 2000;72:131-3.
2. Kochenderfer JN, Kobayashi S, Wieder ED, et al. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002;100:3639-45.
3. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vβ profiles. Br J Haematol 1998;102:1314-22.
4. Killick SB, Mufti G, Cavenagh JD, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003;120:679-84.
5. Yazji S, Giles FJ, Tsimberidou AM, et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003;17:2101-6.
6. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007;21:1436-41.
7. Deeg HJ, Beckham C, Loken MR, et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma 2000;37:405-14.
8. Parker JE, Mufti GJ. Excessive apoptosis in low risk myelodysplastic syndromes (MDS). Leuk Lymphoma 2000;40:1-24.
9. Li X, Bryant E, Deeg HJ. Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol 2004;80:140-5.
10. Baumann I, Scheid C, Koref MS, et al. Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelodysplastic syndrome. Exp Hematol 2002;30:1405-11.
11. Plasilova M, Risitano A, Maciejewski JP. Application of the molecular analysis of the T-cell receptor repertoire in the study of immune-mediated hematologic diseases. Hematology 2003;8:173-81.
12. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000;37:15-29.
13. WU LY, Li X, Chang CK, et al. Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome. Int J Lab Hematol 2008;30:390-9.
14. Greenberg PL, Cox C, Le Beau MM, et al. International prognosis scoring system (IPSS) for evaluating prognosis in myelodysplastic syndrome. Blood 1997; 89: 2079-88.
15. Harris N, Jaffe E, Diebold J, et al. WHO classification of neoplastic diseases of the hematopietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Article House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
16. Kook H, Zeng W, Guibin C, et al. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 2001;29:1270-7.
17. Epperson D, Nakamura R, Saunthararajah Y, et al. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001;25:1075-83.
18. Giovannetti A, Ensoli F, Mazzetta F, et al. CCR5 and CXCR4 chemokine receptor expression and β-chemokine production during early T cell repopulation induced by highly active anti-retroviral therapy. Clin Exp Immunol, 1999;118:87-94.
19. Mart'inez-Jaramillo G, Flores-Figueroa E, Sánchez-Valle E, et al. Comparative analysis of the in vitro proliferation and expansion of hematopoietic progenitors from patients with aplastic anemia and myelodysplasia. Leuk Res 2002;26:955-63.
20. Sloand EM, Mainwaring L, Fuhrer M, et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005;106:841-51.
21. Perez-Diez A, Joncker NT, Choi K, et al CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007;109:5346-54.
22. Sloand EM, Pfannes L, Chen G, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 2007;109:2399-405.
23. Claessens YE, Bouscary D, Dupont JM, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002;99:1594-601.
24. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003;102:3025-7.
25. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002;100:1570-4.
26. Voulgarelis M, Giannouli S, Ritis K, et al. Myelodysplasia associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest 2004;34:690-700.
27. Sloand E, Kim S, Maciejewski JP, et al. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood 2002;100:1185-91.
28. Giannakoulas NC, Karakantza M, Theodorou GL, et al. Clinical relevance of balance between type1 and type 2 immune responses of lymphocyte subpopulations in aplastic anaemia patients. Br J Haematol 2004;124:97-105.